AMAG Pharmaceuticals, Inc. to Host Conference Call to Discuss Financial Results for the Quarter Ended September 30, 2009

LEXINGTON, Mass.–(BUSINESS WIRE)– AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the third quarter ended September 30, 2009 before the U.S. financial markets open on October 29, 2009. The announcement will be followed by a conference call at 8:30 a.m. ET during which management will discuss the Company’s third quarter financial results, development programs, and the recent launch of Feraheme(TM) (ferumoxytol) Injection.

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (702) 495-1202 for international access. A telephone replay will be available from approximately 11:30 a.m. ET on October 29, 2009 through midnight November 2, 2009. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and the replay is 36056615.

The call will be webcast with slides and accessible through the Investors section of the Company’s website at www.amagpharma.com. The webcast replay will be available from approximately 11:30 a.m. ET on October 29, 2009 through midnight November 12, 2009.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG recently received approval from the U.S. Food and Drug Administration to market Feraheme for the treatment of iron deficiency anemia in adult chronic kidney disease patients. For additional company and product information, please visit www.amagpharma.com.

Feraheme(TM) is a trademark of AMAG Pharmaceuticals, Inc.

    Source: AMAG Pharmaceuticals, Inc.